Alvotech to Present at Upcoming Investor Conferences in November

Alvotech, a global biotechnology company specializing in biosimilar medicines, announced that its management team will participate in four major investor conferences across Europe in November 2026, including presentations at UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, DNB Carnegie Healthcare Conference, and SEB Healthcare Seminar. Live audio webcasts will be available on the company's website.

11/02/2026, 7:00 AM • GlobeNewswire

Alvotech kemur fram á fjórum fjárfestaráðstefnum í nóvember

Alvotech, a global biotechnology company specializing in biosimilar medicines, will present at four international investor conferences in November 2026 across the UK, Norway, and Sweden. The company will participate in UBS's biotech conference in London, Jefferies' healthcare conference in London, DNB Carnegie's healthcare conference in Oslo, and SEB's healthcare conference in Stockholm. Live streams and recordings of these presentations will be available on the company's events page.

11/02/2026, 7:00 AM • GlobeNewswire

Alvotech birtir uppgjör fyrstu níu mánaða ársins 2026 þann 11. nóvember nk.

Alvotech announced it will release its nine-month financial results for 2026 on November 11, with a live webcast presentation scheduled for November 12. The company also received FDA approval for an enhanced SIMLANDI® manufacturing process that more than doubles output per batch, increasing manufacturing productivity and freeing capacity to support growing demand across its biosimilars portfolio.

10/28/2026, 7:00 AM • GlobeNewswire

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

Alvotech announced it will release its nine-month and Q3 2026 financial results on November 11, 2026, followed by a webcast and Q&A session on November 12, 2026. The company, a global biosimilar developer, has five approved biosimilars on the market and recently received FDA approval for an enhanced manufacturing process that more than doubles output per batch.

10/28/2026, 7:00 AM • GlobeNewswire

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

Alvotech announced it will release its nine-month and Q3 2026 financial results on November 11, 2026, followed by a webcast and Q&A session on November 12, 2026. The company, a global biosimilar developer, has five approved biosimilars on the market and recently received FDA approval for an enhanced manufacturing process that doubles output per batch.

10/28/2026, 7:00 AM • GlobeNewswire

Transactions of Managers and Closely Associated Persons

Alvotech closed a public offering raising $165 million in aggregate proceeds, with underwriters fully exercising their option to purchase additional shares. The offering included a concurrent private placement where Celtic Lux Holdings acquired 10,133,333 shares at $3.75 per share.

06/22/2026, 6:48 PM • GlobeNewswire

Viðskipti stjórnenda og tengdra aðila

Alvotech successfully closed a public offering raising $165 million in aggregate, with underwriters fully exercising their option to purchase additional shares. The offering included a concurrent private placement where Celtic Lux Holdings purchased 10.133 million shares at $3.75 per share on June 16, 2026.

06/22/2026, 6:48 PM • GlobeNewswire

Alvotech tilkynnir um verð og úthlutun hlutabréfa að andvirði um 152 milljónir dollara í útboði í Bandaríkjunum og lokuðu útboði til fagfjárfesta á Evrópska efnahagssvæðinu

Alvotech (NASDAQ: ALVO) announced a $152 million share offering, comprising an $85 million public offering in the US at $3.75 per share and a $67 million private placement to institutional investors in the EEA. The company plans to use proceeds for biosimilar drug development, working capital, and operational expenses. BofA Securities, Jefferies, and Evercore ISI are joint underwriters.

06/15/2026, 11:50 PM • GlobeNewswire

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

Alvotech priced a $152 million public offering of 22.67 million ordinary shares at $3.75 per share, with an additional concurrent private placement of 17.83 million shares at the same price expected to raise approximately $67 million. The company plans to use net proceeds for biosimilar development, working capital, and potential debt repayment. The offering is expected to close on June 17, 2026, with the private placement closing around June 25, 2026.

06/15/2026, 11:50 PM • GlobeNewswire

Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?

Teva Pharmaceutical has rebounded 97% in 12 months driven by its expanding biosimilars lineup and branded drugs like Austedo. However, the stock now trades at a fair 25x P/E ratio with 2026 revenue expected to be flat to lower. While biosimilars could grow to $800 million by 2027, the narrow-margin business faces intense competition and the easy gains may already be priced in. The analyst recommends watching but not buying.

06/12/2026, 4:05 PM • The Motley Fool

Alvotech files Annual Report with the SEC

Alvotech (NASDAQ: ALVO), an Iceland-based biotechnology company specializing in biosimilar medicines, has filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission. The company has five approved and marketed biosimilars and nine additional candidates in development across multiple therapeutic areas.

03/30/2026, 7:58 PM • GlobeNewswire

Alvotech birtir ársreikning á eyðublaði 20-F

Alvotech announced the publication of its 2025 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The report is available on the SEC website and Alvotech's investor relations page.

03/30/2026, 7:58 PM • GlobeNewswire

Alvotech Files Annual Report with the SEC

Alvotech (NASDAQ: ALVO), an Iceland-based biotechnology company specializing in biosimilar medicines, has filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission. The company has five approved and marketed biosimilars and nine additional candidates in development, supported by a global network of strategic commercial partnerships.

03/30/2026, 7:55 PM • GlobeNewswire

Alvotech birtir ársskýrslu fyrir árið 2025

Alvotech (NASDAQ: ALVO), an Icelandic biotech company founded by Róbert Wessman, has filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission. The company focuses on developing and manufacturing biosimilar medications for patients worldwide, with operations spanning major markets including the United States, Europe, Asia, Latin America, Africa, and the Middle East.

03/30/2026, 7:55 PM • GlobeNewswire

Alvotech Publishes 2025 Annual Report

Alvotech (NASDAQ: ALVO), an Iceland-based biotechnology company specializing in biosimilar medicines, has published and filed its 2025 Annual Report with the SEC on Form 20-F. The company currently has five approved and marketed biosimilars and nine additional candidates in development across multiple therapeutic areas.

03/30/2026, 7:55 PM • GlobeNewswire